Asset Details
Do you wish to reserve the book?
Disseminated Kaposi sarcoma patients exhibit an expanded population of CD8+CD57+ T cells and an immunosenescence profile
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Disseminated Kaposi sarcoma patients exhibit an expanded population of CD8+CD57+ T cells and an immunosenescence profile
Do you wish to request the book?
Disseminated Kaposi sarcoma patients exhibit an expanded population of CD8+CD57+ T cells and an immunosenescence profile
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Disseminated Kaposi sarcoma patients exhibit an expanded population of CD8+CD57+ T cells and an immunosenescence profile
2025
Overview
Kaposi's sarcoma herpesvirus (KSHV) remains the most common opportunistic malignancy that contributes to morbidity and mortality among persons living with HIV (PLWH) worldwide. The immune response in PLWH can exhibit signs of functional exhaustion, characterized by CD57 expression and mitochondrial dysfunction in T-cells. Valganciclovir (VGC), as an add-on therapy in patients with disseminated Kaposi Sarcoma/human immunodeficiency virus (DKS/HIV), modulates the activation of T-cell subsets; however, its effect on the T-cell immunosenescence profile is unclear.
This study evaluated the T-cell immunosenescence profile in DKS/HIV patients who received two treatment schedules: A group received antiretroviral therapy (cART) as conventional therapy (CT, n=10), while a second group received an experimental regimen, consisting of VGC initially plus cART (VGC+cART, n=10) by the fourth week. Mononuclear cells from DKS/HIV patients were obtained at baseline (W
) and at weeks W
and W
of treatment. T-cells were labeled with cell markers such as CD3, CD4, CD8, CD27, CD57, KLRG1, PD-1, TIM-3, and GLUT1, as well as soluble molecules and a proteome profile array of proteins related to proteases.
Data showed that DKS/HIV patients have an increased frequency of GLUT1+ T-cells at diagnosis, which was not modified after treatment initiation. The presence of CD8+CD57+KLRG1+ T-cells was expanded in DKS/HIV patients and maintained across follow-up once VGC+cART treatment was started. Although DKS/HIV patients display high plasma levels of soluble ligands for KLRG1 (E-cadherin) and TIM-3 (Gal-9) at diagnosis, together with proteases associated with the regulation of T-cells and the induction of T-cell immunosenescence, both treatment schedules reduce their soluble levels after 12 weeks of follow-up.
The microenvironment generated in DKS/HIV patients increases the frequency of T-cells exhibiting an immunosenescence phenotype, and this effect is independent of the treatment schedule used, suggesting that during coinfection, a chronic immunosuppressive microenvironment may develop, impairing immune surveillance and resilience. These results could be explored to identify novel therapeutic approaches.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ CD8-Positive T-Lymphocytes - immunology
/ CD8-Positive T-Lymphocytes - metabolism
/ Disease
/ Enzymes
/ Female
/ Hepatitis A Virus Cellular Receptor 2
/ Herpesvirus 8, Human - immunology
/ HIV
/ HIV Infections - drug therapy
/ human herpesvirus-8/Kaposi sarcoma herpesvirus
/ Human immunodeficiency virus
/ Humans
/ Male
/ Plasma
/ Sarcoma
/ Sarcoma, Kaposi - drug therapy
/ Sarcoma, Kaposi - immunology
/ Software
